Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.
Since Oct 22, 2025
Transactions
124
Purchases
0
Sales
124
Purchase value
$0.00
Sale value
$115.61M
Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
4Rule 10b5-1 plan disclosed
Filed Oct 19, 2026Period of report Oct 15, 20260001763494-26-000008
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 15, 2026
Common StockF1F2
128,065
$52.9672
$6.78M
548,556
Direct
SaleOct 15, 2026
Common StockF1F3
37,270
$54.1997
$2.02M
Filing footnotes · 6
F1This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2The weighted average sale price for the transaction reported was $52.9672, and the range of prices were between $52.63 and $53.6250. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3The weighted average sale price for the transaction reported was $54.1997, and the range of prices were between $53.63 and $54.62. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The weighted average sale price for the transaction reported was $55.0179, and the range of prices were between $54.63 and $55.57. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5The stock option is fully vested and exercisable.
F6One-fourth of the shares subject to the stock option vested and became exercisable on January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.
Filed Sep 17, 2026Period of report Sep 15, 20260001789617-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
4Rule 10b5-1 plan disclosed
Filed Sep 17, 2026Period of report Sep 15, 20260001763494-26-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Rote William E.Chief Research Officer
4Rule 10b5-1 plan disclosed
Filed Sep 17, 2026Period of report Sep 15, 20260001698262-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Cline Christopher R.CHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Sep 17, 2026Period of report Sep 15, 20260001943192-26-000006
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Inrig JulaEVP, Head of R&D & CMO
4Rule 10b5-1 plan disclosed
Filed Sep 17, 2026Period of report Sep 15, 20260001902368-26-000008
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
4Rule 10b5-1 plan disclosed
Filed Sep 17, 2026Period of report Sep 15, 20260001882909-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Reed Elizabeth eChief Legal Officer and GC
4Rule 10b5-1 plan disclosed
Filed Sep 17, 2026Period of report Sep 15, 20260001283303-26-000010
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Meckler Jeffrey ADirector
4Rule 10b5-1 plan disclosed
Filed Sep 11, 2026Period of report Sep 10, 20260001506916-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Cline Christopher R.CHIEF FINANCIAL OFFICER
4
Filed Sep 3, 2026Period of report Sep 2, 20260001943192-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleSep 2, 2026
Common StockF1
642
$66.37
$42.61K
118,016
Direct
Lyons Gary aDirector
4Rule 10b5-1 plan disclosed
Filed Aug 19, 2026Period of report Aug 17, 20260001123343-26-000010
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Baynes Roy D.Director
4Rule 10b5-1 plan disclosed
Filed Jun 16, 2026Period of report Jun 12, 20260001680739-26-000014
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Coughlin TimothyDirector
4Rule 10b5-1 plan disclosed
Filed Jun 16, 2026Period of report Jun 12, 20260001376043-26-000010
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Coughlin TimothyDirector
4Rule 10b5-1 plan disclosed
Filed May 19, 2026Period of report May 15, 20260001376043-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Cline Christopher R.CHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed May 6, 2026Period of report May 4, 20260001943192-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Inrig JulaCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed May 6, 2026Period of report May 4, 20260001902368-26-000006
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
4Rule 10b5-1 plan disclosed
Filed May 6, 2026Period of report May 4, 20260001763494-26-000006
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Rote William E.Chief Research Officer
4Rule 10b5-1 plan disclosed
Filed May 6, 2026Period of report May 4, 20260001698262-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Reed Elizabeth eChief Legal Officer and GC
4Rule 10b5-1 plan disclosed
Filed May 6, 2026Period of report May 4, 20260001283303-26-000009
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Heerma PeterCHIEF COMMERCIAL OFFICER
4
Filed May 6, 2026Period of report May 4, 20260001789617-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMay 5, 2026
Common StockF2
2,174
$46.65
$101.42K
140,684
Direct
Baynes Roy D.Director
4Rule 10b5-1 plan disclosed
Filed May 6, 2026Period of report May 5, 20260001680739-26-000008
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Meckler Jeffrey ADirector
4Rule 10b5-1 plan disclosed
Filed May 6, 2026Period of report May 4, 20260001506916-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Baynes Roy D.Director
4Rule 10b5-1 plan disclosed
Filed May 4, 2026Period of report May 1, 20260001680739-26-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Rote William E.Chief Research Officer
4Rule 10b5-1 plan disclosed
Filed Apr 23, 2026Period of report Apr 22, 20260001698262-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Cline Christopher R.CHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Apr 15, 2026Period of report Apr 13, 20260001943192-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Inrig JulaCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Apr 15, 2026Period of report Apr 13, 20260001902368-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
4Rule 10b5-1 plan disclosed
Filed Apr 15, 2026Period of report Apr 13, 20260001763494-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Reed Elizabeth eChief Legal Officer and GC
4Rule 10b5-1 plan disclosed
Filed Apr 15, 2026Period of report Apr 13, 20260001283303-26-000008
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
4Rule 10b5-1 plan disclosed
Filed Apr 16, 2026Period of report Apr 14, 20260001882909-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Baynes Roy D.Director
4Rule 10b5-1 plan disclosed
Filed Apr 16, 2026Period of report Apr 14, 20260001680739-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Lyons Gary aDirector
4Rule 10b5-1 plan disclosed
Filed Apr 16, 2026Period of report Apr 14, 20260001123343-26-000002
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Heerma PeterCHIEF COMMERCIAL OFFICER
4
Filed Apr 15, 2026Period of report Apr 13, 20260001789617-26-000002
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleApr 14, 2026
Common StockF2
7,215
$41.9288
$302.52K
138,608
Direct
Baynes Roy D.Director
4Rule 10b5-1 plan disclosed
Filed Apr 7, 2026Period of report Apr 6, 20260001680739-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
4Rule 10b5-1 plan disclosed
Filed Apr 2, 2026Period of report Apr 1, 20260001763494-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Reed Elizabeth eChief Legal Officer and GC
4Rule 10b5-1 plan disclosed
Filed Apr 2, 2026Period of report Apr 1, 20260001283303-26-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Reed Elizabeth eChief Legal Officer and GC
4Rule 10b5-1 plan disclosed
Filed Mar 18, 2026Period of report Mar 16, 20260001283303-26-000006
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
4Rule 10b5-1 plan disclosed
Filed Feb 24, 2026Period of report Feb 20, 20260001763494-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Reed Elizabeth eChief Legal Officer and GC
4Rule 10b5-1 plan disclosed
Filed Feb 19, 2026Period of report Feb 17, 20260001283303-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Cline Christopher R.CHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Feb 5, 2026Period of report Feb 4, 20260001943192-26-000002
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Inrig JulaCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Feb 5, 2026Period of report Feb 4, 20260001902368-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Reed Elizabeth eChief Legal Officer and GC
4Rule 10b5-1 plan disclosed
Filed Feb 5, 2026Period of report Feb 4, 20260001283303-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Cline Christopher R.CHIEF FINANCIAL OFFICER
4
Filed Feb 3, 2026Period of report Jan 31, 20260001943192-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleFeb 3, 2026
Common StockF2
7,242
$32.12
$232.61K
112,971
Direct
Inrig JulaCHIEF MEDICAL OFFICER
4
Filed Feb 3, 2026Period of report Jan 31, 20260001902368-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleFeb 3, 2026
Common StockF2
6,956
$32.12
$223.43K
107,485
Direct
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
4
Filed Feb 3, 2026Period of report Jan 31, 20260001882909-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleFeb 3, 2026
Common StockF2
4,333
$32.12
$139.18K
49,080
Direct
Heerma PeterCHIEF COMMERCIAL OFFICER
4
Filed Feb 3, 2026Period of report Jan 31, 20260001789617-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleFeb 3, 2026
Common StockF2
7,310
$32.12
$234.80K
131,823
Direct
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
4Rule 10b5-1 plan disclosed
Filed Feb 3, 2026Period of report Jan 31, 20260001763494-26-000002
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Rote William E.Chief Research Officer
4Rule 10b5-1 plan disclosed
Filed Feb 3, 2026Period of report Jan 31, 20260001698262-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Reed Elizabeth eChief Legal Officer and GC
4
Filed Feb 3, 2026Period of report Jan 31, 20260001283303-26-000002
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleFeb 3, 2026
Common StockF2
7,175
$32.12
$230.46K
108,205
Direct
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
4Rule 10b5-1 plan disclosed
Filed Jan 27, 2026Period of report Jan 23, 20260001763494-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Reed Elizabeth eChief Legal Officer and GC
4Rule 10b5-1 plan disclosed
Filed Jan 21, 2026Period of report Jan 20, 20260001283303-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.
511,286
Direct
SaleOct 15, 2026
Common StockF1F4
78,400
$55.0179
$4.31M
432,886
Direct
Sep 17, 2026
Common StockF2F9
8,282
$65.0709
$538.92K
117,066
Direct
SaleSep 16, 2026
Common StockF2F7
93,604
$63.2471
$5.92M
196,179
Direct
SaleSep 16, 2026
Common StockF2F8
79,113
$63.6546
$5.04M
117,066
Direct
SaleSep 15, 2026
Common StockF2F3
71,938
$62.0517
$4.46M
147,318
Direct
SaleSep 15, 2026
Common StockF2F4
27,421
$62.5936
$1.72M
119,897
Direct
SaleSep 15, 2026
Common StockF2F5
1,400
$63.6521
$89.11K
118,497
Direct
SaleSep 15, 2026
Common StockF2F6
1,431
$65.3093
$93.46K
117,066
Direct
Filing footnotes · 12
F1Includes 1,382 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.
F10The stock option is fully vested and exercisable.
F11One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
F12One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.
F2This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F3The weighted average sale price for the transaction reported was $62.0517, and the range of prices were between $61.43 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The weighted average sale price for the transaction reported was $62.5936, and the range of prices were between $62.43 and $63.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5The weighted average sale price for the transaction reported was $63.6521, and the range of prices were between $63.56 and $63.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6The weighted average sale price for the transaction reported was $65.3093, and the range of prices were between $65.30 and $65.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F7The weighted average sale price for the transaction reported was $63.2471, and the range of prices were between $62.50 and $63.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F8The weighted average sale price for the transaction reported was $63.6546, and the range of prices were between $63.50 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F9The weighted average sale price for the transaction reported was $65.0709, and the range of prices were between $65.00 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F1This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F7The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F8The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F9The stock option is fully vested and exercisable.
F1Includes 271 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.
F2This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F3The weighted average sale price for the transaction reported was $61.994, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The weighted average sale price for the transaction reported was $62.6552 and the range of prices were between $62.41 and $63.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5The weighted average sale price for the transaction reported was $63.6508, and the range of prices were between $63.49 and $63.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided
F6The weighted average sale price for the transaction reported was $63.1205, and the range of prices were between $62.47 and $63.4650. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F7The weighted average sale price for the transaction reported was $63.6126, and the range of prices were between $63.47 and $63.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F8The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.
F2The weighted average sale price for the transaction reported was $61.9969, and the range of prices were between $61.38 and $62.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3The weighted average sale price for the transaction reported was $62.6079, and the range of prices were between $62.38 and $63.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The weighted average sale price for the transaction reported was $63.6865, and the range of prices were between $63.59 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2The weighted average sale price for the transaction reported was $62.0167, and the range of prices were between $61.40 and $62.39. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3The weighted average sale price for the transaction reported was $62.6242, and the range of prices were between $62.40 and $63.365. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The weighted average sale price for the transaction reported was $63.685, and the range of prices were between $63.58 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.
F1This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5The stock option is fully vested and exercisable.
F6One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
F7One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.
F1Includes 178 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.
F2This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F3The weighted average sale price for the transaction reported was $62.0255, and the range of prices were between $61.44 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The weighted average sale price for the transaction reported was $62.6326, and the range of prices were between $62.44 and $63.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5The weighted average sale price for the transaction reported was $63.6902, and the range of prices were between $63.59 and $63.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028.
F2The weighted average sale price for the transaction reported was $65.3917, and the range of prices were between $64.835 and $65.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3The weighted average sale price for the transaction reported was $66.15, and the range of prices were between $65.93 and $66.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The weighted average sale price for the transaction reported was $67.4634, and the range of prices were between $66.93 and $67.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5The weighted average sale price for the transaction reported was $68.088, and the range of prices were between $67.94 and $68.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6The stock option is fully vested and exercisable.
F1Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F1This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.
F2The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F7The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.
F2The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2The weighted average sale price for the transaction reported was $50.0747, and the range of prices were between $50.00 and $50.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F1On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.
F2Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F3This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
F4Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.
F1This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.
F3Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F4This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
F5One-fourth of the shares subject to the stock option vested and become exercisable on January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.
F6Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.
F1On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.
F2This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
F3Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.
F1On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.
F2This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
F3Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.
F1This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.
F2On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.
F3Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F4This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
F5The stock option is fully vested and exercisable.
F6Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.
F1On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.
F2Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F3Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.
F1This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.
F2The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on November 17, 2025 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on May 18, 2016 with an expiration date of May 18, 2026.
F2The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.
F2The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
F1On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.
F2Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F3This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
F4Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F5This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
F1On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.
F2Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F3This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
F1On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.
F2This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
F3The weighted average sale price for the transaction reported was $41.01, and the range of prices were between $40.51 and $41.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4The weighted average sale price for the transaction reported was $41.75, and the range of prices were between $41.52 and $42.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F1On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.
F2This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.
F3Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F4This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
F5The weighted average sale price for the transaction reported was $41.62, and the range of prices were between $41.255 and $42.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F6The weighted average sale price for the transaction reported was $42.53, and the range of prices were between $42.335 and $42.66. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F7The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
F3One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.
F4One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.
F1This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.
F2The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on November 11, 2025 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 18, 2026.
F2The stock option is fully vested and exercisable.
F1On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.
F2Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F1This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 9, 2018.
F2The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020.
F2The weighted average sale price for the transaction reported was $30.55, and the range of prices were between $30.13 and $31.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3The weighted average sale price for the transaction reported was $31.46, and the range of prices were between $31.15 and $31.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020.
F2The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.
F2The weighted average sale price for the transaction reported was $28.0861, and the range of prices were between $27.66 and $28.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2The weighted average sale price for the transaction reported was $30.0961, and the range of prices were between $30.00 and $30.325. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.
F2The weighted average sale price for the transaction reported was $27.504, and the range of prices were between $27.01 and $27.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3The weighted average sale price for the transaction reported was $28.262, and the range of prices were between $28.09 and $28.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4The stock option is fully vested and exercisable.
F1This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
F2The weighted average sale price for the transaction reported was $32.14, and the range of prices were between $31.645 and $32.645. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F1This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
F2The weighted average sale price for the transaction reported was $32.11, and the range of prices were between $31.65 and $32.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3The weighted average sale price for the transaction reported was $32.85, and the range of prices were between $32.80 and $32.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F1This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
F2The weighted average sale price for the transaction reported was $32.07, and the range of prices were between $31.63 and $32.61. Upon request by the SEC staff, the Issuer, or any security holder of theIssuer, full information regarding the number of shares sold at each price will be provided.
F3The weighted average sale price for the transaction reported was $32.74, and the range of prices were between $32.64 and $32.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F1Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
F2Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F3One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
F1Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
F2Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F3One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
F1Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
F2Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F3One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
F1Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
F2Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F3One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
F1Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
F2This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3The weighted average sale price for the transaction reported was $32.06, and the range of prices were between $31.52 and $32.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The weighted average sale price for the transaction reported was $32.70, and the range of prices were between $32.5248 and $32.88. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
F1Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
F2This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
F1Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
F2Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F3One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
F1This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2The weighted average sale price for the transaction reported was $30.0127, and the range of prices were between $30.00 and $30.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3The weighted average sale price for the transaction reported was $30.097, and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The stock option is fully vested and exercisable.
F1Includes 392 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 28, 2025.
F2This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.
F3The weighted average sale price for the transaction reported was $27.3420, and the range of prices were between $26.910 and $27.590. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4The stock option is fully vested and exercisable.
